<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most common form of <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo>, and its incidence is rising as the population ages </plain></SENT>
<SENT sid="1" pm="."><plain>AF is therefore a growing source of <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality due to thromboembolic complications and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The risk of embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> is multiplied by about 5.6-fold in non rheumatic AF and by 17.6-fold in rheumatic AF <z:hpo ids='HP_0001297'>Strokes</z:hpo> due to AF are often fatal or disabling </plain></SENT>
<SENT sid="3" pm="."><plain>Paroxysmal and permanent <z:mp ids='MP_0006109'>fibrillation</z:mp> are associated with a similar thromboembolic risk </plain></SENT>
<SENT sid="4" pm="."><plain>Embolic complications arise from the left atrium or the left atrial appendage </plain></SENT>
<SENT sid="5" pm="."><plain>Known risk factors in patients with AF include a history of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> or <z:hpo ids='HP_0001297'>stroke</z:hpo>, age &gt; 75 years, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, rheumatic valve disease, mechanical prosthetic valves, arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, female gender and atherosclerotic <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> are associated with an intermediate risk of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="6" ids="28384">Vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> therapy targeting an INR of 2 to 3 reduces the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> by two-thirds in patients with AF, and causes <z:mp ids='MP_0001914'>bleeding</z:mp> in 1.4 % to 3.6 % of patients </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:mp ids='MP_0001914'>bleeding</z:mp> risk can be evaluated with the CHADS2 scale </plain></SENT>
<SENT sid="9" pm="."><plain>Aspirin (75/300 mg per day) reduces the risk of cerebral <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> by about 21% </plain></SENT>
<SENT sid="10" pm="."><plain>Current guidelines recommend <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> or dabigatran anticoagulation for patients with a CHADS2 score of 2 </plain></SENT>
<SENT sid="11" pm="."><plain>Patients with a score of 0 should receive either aspirin or no drug therapy, while patients with a score of 1 may receive either a <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> or aspirin </plain></SENT>
<SENT sid="12" pm="."><plain>After successful AF ablation, the existing antithrombotic strategy should be pursued New strategies based on antithrombin or anti-Xa medications will probably have a better risk-benefit ratio </plain></SENT>
</text></document>